Santaris Pharma begins human clinical testing of the world's first medicine targeted at a human microRNA
SPC3649 (LNA-antimiR-122) being developed as a potential new therapy for Hepatitis C virus (HCV) infection
30-May-2008 -
Santaris Pharma announced that it has commenced a Phase I human volunteer trial of SPC3649 (LNA-antimiRTM-122), the world's first microRNA medicine to be tested in man, according to the company. The study is being conducted by PhaseOneTrials A/S, Copenhagen, and will include a maximum of 48 ...
acids
clinical trials
genes
+4